North Dallas Bank & Trust Co. Purchases Shares of 1,383 Thermo Fisher Scientific Inc. $TMO

North Dallas Bank & Trust Co. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,383 shares of the medical research company’s stock, valued at approximately $801,000.

A number of other institutional investors have also bought and sold shares of the company. Alteri Wealth LLC boosted its position in Thermo Fisher Scientific by 37.8% during the fourth quarter. Alteri Wealth LLC now owns 1,196 shares of the medical research company’s stock valued at $693,000 after acquiring an additional 328 shares during the last quarter. Pettyjohn Wood & White Inc. boosted its position in Thermo Fisher Scientific by 20.8% during the fourth quarter. Pettyjohn Wood & White Inc. now owns 1,038 shares of the medical research company’s stock valued at $601,000 after acquiring an additional 179 shares during the last quarter. Eldridge Investment Advisors Inc. boosted its position in Thermo Fisher Scientific by 6.2% during the fourth quarter. Eldridge Investment Advisors Inc. now owns 752 shares of the medical research company’s stock valued at $436,000 after acquiring an additional 44 shares during the last quarter. Marks Group Wealth Management Inc boosted its position in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Marks Group Wealth Management Inc now owns 5,398 shares of the medical research company’s stock worth $3,128,000 after purchasing an additional 47 shares in the last quarter. Finally, Gaddis Premier Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $1,255,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 5.2%

NYSE:TMO opened at $493.91 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $183.55 billion, a price-to-earnings ratio of 27.15, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The firm has a 50-day moving average price of $479.96 and a two-hundred day moving average price of $529.52.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TMO. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective on the stock. Barclays cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Morgan Stanley reissued an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $613.67.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.